Nitric Oxide Gas

Phase 3Small molecule

XXijing Hospital

Nitric Oxide Gas is one of 6 small molecule programs targeting Cardiopulmonary Bypass. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiopulmonary BypassRecruiting

Cardiopulmonary BypassPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Cardiopulmonary Bypass

#DrugCompanyPhaseTrials

Nitric Oxide Gas

XXijing Hospital

Phase 3

1 2

Primacor

Sanofi

Preclinical

2 3

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 4

Aprotinin

Bayer

Preclinical

1 5

Dibenzyline

AAdvanz Pharma

Preclinical

1 6

Protamine Sulfate

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Cardiopulmonary Bypass

NCT06702553

Clinical

Trials by Indication[1]

COVID-192 trials

Inhaled NO in Surgical Patients With Recent COVID-19 Infection

Completed·XXijing Hospital·Phase 2·NCT05721144·660 enrolled

Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED

Terminated·MMassachusetts General Hospital·Phase 2·NCT04338828·47 enrolled

Severe Acute Respiratory Syndrome2 trials

Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19

Completed·MMassachusetts General Hospital·Phase 2·NCT04306393·200 enrolled

Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.

Withdrawn·XXijing Hospital·Phase 2·NCT04290871

Cardiopulmonary Bypass1 trial

Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass

Recruiting·XXijing Hospital·Phase 3·NCT06702553·3,650 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Nitric Oxide Gas. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nitric Oxide Gas compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nitric Oxide Gas. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Xijing Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: XXijing Hospital

Nitric Oxide Gas

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

COVID-192 trials

Severe Acute Respiratory Syndrome2 trials

Cardiopulmonary Bypass1 trial

References

Drug Info

Quick Facts

Related News